Carbamazepine and Mifepristone interaction
Carbamazepine and Mifepristone: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Mifepristone label · effective 2025-09-25
Avoid co-administration of mifepristone and CYP3A inducers such as rifampin, rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, and St.
CYP3A inducers: Do not use mifepristone with CYP3A inducers ( 7.3 ).
The dose of mifepristone should be limited to 900 mg, and strong inhibitors of CYP3A should be used only when necessary. [See Dosage and Administration ( 2.4 ), Warnings & Precautions ( 5.6 ), and Clinical Pharmacology ( 12.3 )] 7.3 CYP3A Inducers No medications that induce CYP3A have been studied when co-administered with mifepristone.
From the Carbamazepine (EQUETRO) label · effective 2025-08-19
EQUETRO can reduce the effectiveness of hormonal contraceptives.
Equetro may decrease the effectiveness of hormonal contraceptives.
It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase.
EQUETRO decreases the concentrations of the following drugs through induction of their metabolism: Hormonal Contraceptives (CYP3A4 Substrates) EQUETRO is a strong inducer of CYP3A4.
EQUETRO can increase the metabolism of certain hormonal contraceptives (through CYP3A4 induction) such as oral and subdermal implant contraceptives, leading to significantly lower plasma concentrations of hormones.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.